MedTrace Logo

Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With Hypertension

NCT06713785 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2024-12-03

No results posted yet for this study

Summary

The primary objective of the study is to assess precision dosing of amlodipine to deliver reductions in blood pressure in patients with primary hypertension and inadequate BP control by up-titration of amlodipine in 1mg increments

Conditions

Interventions

DRUG

Amlodipine

Amlodipine 1mg/ml Oral Solution

Sponsors & Collaborators

  • INNOVATEUK

    collaborator UNKNOWN

  • Closed Loop Medicine Ltd

    collaborator UNKNOWN

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • David Collier, Dr · Clinical Director

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-26
Primary Completion
2021-01-31
Completion
2021-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06713785 on ClinicalTrials.gov